Search PubMed⌕ Search

Biomedical subjects

W M Gallmeier

Publications and source records attributed to W M Gallmeier.

At least 73 records · Page 4Linked to original sources
PubMed1976

[Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].

In 18 patients with advanced Hodgkin's disease, refractory to previous 'C-MOPP' treatment, a new therapeutic protocol of adriamycin, DTIC, CCNU and bleomycin was introduced. Three patients who had previously failed to respond to any other chemotherapy failed also to respond to the new one. But two complete and 11 partial remissions were obtained in the other 15 patients who had previously responded to C-MOPP before becoming refractory to it. Two patients had further progression of the disease during the new treatment.

Adult↗
PubMed1976

[cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma (author's transl)].

cis-Diamino-dichloro-platinum (II) (DDP, NSC-119875) is an inorganic compound with cytostatic properties which have only recently been appreciated. DDP has an action which may tentatively be described as alkylating through some, as yet unknown, metabolic product. In a phase I study the effectiveness against testicular neoplasma had been established. A prospective trial was, therefore, conducted to test the drug's efficiency in patients with disseminated non-seminomatous testicular cancer refractory to all previously used combinations of chemotherapy. In a group of 22 patients the results were: 1 CR, 14 PR, 2 NC, and 5 PD. Because of these results, DDP was made part of an induction regime for disseminated and non-seminomatous testicular tumors.

Adolescent↗
PubMed1975

[New chemotherapy (adriamycin, belomycin and vincristin) of metastasizing malignant testicular teratoma (author's transl)].

In a prospective study 18 patients with metastasizing testicular teratomas were treated with adriamycin, bleomycin and vincristin. Sixteen could be fully evaluated: 12 in stage IV (visceral metastases), three in stage III (lymphondular involvement beyond the diaphragm) and one with advanced stage II (iliac, para-aortic and inguinal nodes). None of the patients had previously received chemotherapy. Toxic side-effects were not severe enough to prevent 12 patients from being treated on an outpatient basis. Complete remission occurred in five, with four of them still in remission two, eight, ten and eleven months later. Partial remission (50% decrease in tumour size for at least four weeks) occurred in three, with one still improving. No change was noted for 11 months in a patient with advanced pulmonary disease. Progression under therapy occurred in seven patients and in some of them there was an initial response which did not, however, meet the criteria of partial remission. The therapeutic results as well as toxicity suggest that this regime is superior to actinomycin D montherapy and various previously used combinations.

Adult↗
PubMed1975

[Immunosuppressive therapy in pure red cell aplasia].

Acquired erythroblastic aplasia of adults is a rare disease characterised by the absence of red cell precursors in the bone marrow. In a 34-year-old female patient the disease has been known for seven years. A partial remission had at first been achieved with glucocorticoids but regular transfusions had been necessary since 1971. Treatment with cyclophosphamide produced a remission which has lasted for over twelve months up to now. Histology of the bone marrow biopsy shows the appearance of active erythropoiesis after cyclophosphamide treatment which reflects well the clinical course.

Adult↗
PubMed1975

[Chemotherapy of metastasizing breast cancers. Indications and results].

Combined treatment with three or five chemotherapeutic drugs was given to 115 women with metastasizing breast cancer. These were unselected cases. Three drugs (cyclophosphamide, methotrexate and prednisone) were given to 49 patients, with remissions occurring in 28, arrest in a further five. Five drugs (additional to the three mentioned ones: vincristine and 5-fluorouracil) were given to 66, with remission in 45 and arrest of the disease in another eight. There was no certain difference between the response to the two forms of treatment. Mean survival time for both forms was 13 months in the remission group and six months in the failure group.

Bone Neoplasms↗